340 related articles for article (PubMed ID: 20920851)
1. [Antineoplastic drug-induced neutropenia: use of granulocyte colony stimulating factors].
Carrato A; Guillén-Ponce C; Grande-Pulido E
Farm Hosp; 2010 Mar; 34 Suppl 1():8-11. PubMed ID: 20920851
[TBL] [Abstract][Full Text] [Related]
2. [Tips on the use of granulocyte colony-stimulating factors in cancer patients predisposed to chemotherapy - induced febrile neutropenia].
Murakawa Y
Gan To Kagaku Ryoho; 2013 Jun; 40(6):693-6. PubMed ID: 23863645
[TBL] [Abstract][Full Text] [Related]
3. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
4. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomics of granulocyte colony-stimulating factor: a critical review.
Barnes G; Pathak A; Schwartzberg L
Adv Ther; 2014 Jul; 31(7):683-95. PubMed ID: 24989316
[TBL] [Abstract][Full Text] [Related]
6. [Primary and secondary prophylactic administration of granulocyte-colony stimulating factor(G-CSF)for febrile neutropenia].
Uchino K; Baba E
Gan To Kagaku Ryoho; 2014 Jun; 41(6):691-3. PubMed ID: 25129081
[TBL] [Abstract][Full Text] [Related]
7. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
Aapro MS; Cameron DA; Pettengell R; Bohlius J; Crawford J; Ellis M; Kearney N; Lyman GH; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2006 Oct; 42(15):2433-53. PubMed ID: 16750358
[TBL] [Abstract][Full Text] [Related]
8. The role of colony-stimulating factors and granulocyte transfusion in treatment options for neutropenia in children with cancer.
Liang DC
Paediatr Drugs; 2003; 5(10):673-84. PubMed ID: 14510625
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic strategies for chemotherapy-induced neutropenia in patients with solid tumors.
Koinis F; Nintos G; Georgoulias V; Kotsakis A
Expert Opin Pharmacother; 2015; 16(10):1505-19. PubMed ID: 26077189
[TBL] [Abstract][Full Text] [Related]
10. Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia.
Ricotta R; Cerea G; Schiavetto I; Maugeri MR; Pedrazzoli P; Siena S
Future Oncol; 2006 Dec; 2(6):667-76. PubMed ID: 17155894
[TBL] [Abstract][Full Text] [Related]
11. Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended?
Klastersky J; Awada A; Aoun M; Paesmans M
Curr Opin Oncol; 2009 Jul; 21(4):297-302. PubMed ID: 19509500
[TBL] [Abstract][Full Text] [Related]
12. Biosimilar pegfilgrastim and adherence to guidelines for chemotherapy-induced neutropenia and infections in cancer patients.
Danova M; Antonuzzo A; Spandonaro F; Pronzato P
Infez Med; 2020 Mar; 28(1):127-129. PubMed ID: 32172272
[TBL] [Abstract][Full Text] [Related]
13. Review of granulocyte colony-stimulating factors in the treatment of established febrile neutropenia.
Pérez Velasco R
J Oncol Pharm Pract; 2011 Sep; 17(3):225-32. PubMed ID: 20562168
[TBL] [Abstract][Full Text] [Related]
14. How to manage neutropenia in multiple myeloma.
Palumbo A; Bladé J; Boccadoro M; Palladino C; Davies F; Dimopoulos M; Dmoszynska A; Einsele H; Moreau P; Sezer O; Spencer A; Sonneveld P; San Miguel J
Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):5-11. PubMed ID: 22178143
[TBL] [Abstract][Full Text] [Related]
15. When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?
Adams JR; Angelotta C; Bennett CL
J Clin Oncol; 2006 Jul; 24(19):2975-7. PubMed ID: 16682722
[No Abstract] [Full Text] [Related]
16. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group.
Ozkaynak MF; Krailo M; Chen Z; Feusner J
Pediatr Blood Cancer; 2005 Sep; 45(3):274-80. PubMed ID: 15806544
[TBL] [Abstract][Full Text] [Related]
17. Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors.
Danova M; Barni S; Del Mastro L; Danesi R; Pappagallo GL
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1303-13. PubMed ID: 21916584
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
Bhana N
Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
[TBL] [Abstract][Full Text] [Related]
19. Risk assessment and guidelines for first-cycle colony-stimulating factor use in the management of chemotherapy-induced neutropenia.
Crawford J
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):22-8. PubMed ID: 16736985
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization.
Crea F; Giovannetti E; Zinzani PL; Danesi R
Crit Rev Oncol Hematol; 2009 Oct; 72(1):21-44. PubMed ID: 19111474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]